0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
This Month in Archives of Dermatology |

This Month in Archives of Dermatology FREE

Arch Dermatol. 2011;147(10):1142. doi:10.1001/archdermatol.2011.276.
Text Size: A A A
Published online

REVERSIBLE POSTERIOR LEUKOENCEPHALOPATHY SYNDROME IN A PATIENT TREATED WITH USTEKINUMAB

Ustekinumab is a fully human immunoglobulin that binds to important cytokines in the pathogenesis of psoriasis. In this case report, Gratton et al describe a single case of reversible posterior leukoencephalopathy syndrome (RPLS) observed in a ustekinumab clinical trial for psoriasis. A reversible neurologic syndrome, RPLS is characterized by acute headache, visual disturbances, altered mental status, seizures, transient cerebral edema, and infarction in the posterior brain. The syndrome is often associated with hypertension, autoimmune diseases, and treatment with immunosuppressive agents. The clinical features of this case were atypical of drug-associated RPLS. Although the relationship between ustekinumab and RPLS remains unclear, this case emphasizes the need for dermatologists to recognize the syndrome and refer patients for appropriate evaluation and treatment.

See Article

THE IMPACT OF PRURITUS ON QUALITY OF LIFE

Several studies have attempted to demonstrate that chronic pruritus has a significant effect on health-related quality of life (QoL). Chronic pain and chronic pruritus share many similarities, and in this cross-sectional study, Kini et al determine the QoL impact of these 2 conditions by measuring health utility scores. Chronic pruritus was found to have a substantial impact on QoL, comparable to that of pain. The severity of symptoms and use of support networks are factors that determine the degree to which patients are affected by their symptoms.

See Article

LONG-TERM OUTCOME OF SPITZ-TYPE MELANOCYTIC TUMORS

Spitz tumors have long drawn interest because a reasonable subset of these lesions appears to metastasize and yet not prove fatal. In this case series drawn from a pathology database, Sepehr et al demonstrate that the long-term clinical outcome of patients with Spitz tumors is good, with a highly favorable prognosis. An increased risk of melanoma was seen among patients with classic Spitz nevus as well as those with atypical Spitz tumors. The authors suggest that minimizing aggressive treatment for localized lesions and offering continued surveillance for rare relapse and subsequent melanomas is warranted.

See Article

EFFICACY OF IMIQUIMOD CREAM, 5%, FOR LENTIGO MALIGNA AFTER COMPLETE EXCISION

Twelve case series have reported a variable response rate of lentigo maligna (LM) to imiquimod, but these studies varied widely in methodology. In this open-label before-and-after interventional study, Ly et al use imiquimod cream, 5%, 5 days a week for 12 weeks to treat 43 patients with LM, and then the original lesion was then excised. A total of 53% of patients demonstrated histopathologic clearance of LM, and the positive predictive value of visible inflammation at the treatment site was low. Imiquimod cream, 5%, as monotherapy has lower efficacy in treating LM than does surgical excision, but its efficacy may be comparable to that of other nonsurgical options, and close follow-up of patients treated with this technique is warranted.

See Article

INTERLEUKIN 23 EXPRESSION IN PYODERMA GANGRENOSUM AND TARGETED THERAPY WITH USTEKINUMAB

Interleukin 23 (IL-23) is involved in the pathogenesis of Crohn disease, with which pyoderma gangrenosum (PG) may be associated. Because IL-23 plays a critical role in driving inflammation and neutrophil production in inflammatory bowel diseases and psoriasis, PG may be driven by similar mechanisms. In this case report, Guenova et al demonstrate an IL-23 –dominated inflammatory infiltrate in a case of PG, as well as complete resolution of the ulcer at week 14 of treatment. Six months after the last ustekinumab dose, no relapse was observed.

 Image not available.

See Article

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

247 Views
0 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs